Please login to the form below

Not currently logged in
Email:
Password:

Paul Stockdale joins Oxford BioDynamics as CFO

He takes over from Katie Long at the UK biotech

Paul Stockdale has joined Oxford BioDynamics as its new chief financial officer and as an executive director on the UK biotech’s board.

He takes over from Katie Long, who has returned to her role within Tessera Investment Management, having previously established and led Oxford BioDynamics’ finance function.

Stockdale arrives at the company from e-Therapeutics, where he had been financial controller since 2012, and has also previously served at Deloitte as a senior manager.

A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

15th September 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....